KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Net Margin (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Net Margin for 15 consecutive years, with 1.94% as the latest value for Q4 2025.

  • Quarterly Net Margin fell 1077.0% to 1.94% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 5.37% through Dec 2025, down 1654.0% year-over-year, with the annual reading at 5.36% for FY2025, 1652.0% down from the prior year.
  • Net Margin for Q4 2025 was 1.94% at Supernus Pharmaceuticals, up from 23.49% in the prior quarter.
  • The five-year high for Net Margin was 21.91% in Q3 2024, with the low at 23.49% in Q3 2025.
  • Average Net Margin over 5 years is 4.92%, with a median of 4.49% recorded in 2022.
  • The sharpest move saw Net Margin soared 3229bps in 2024, then plummeted -4540bps in 2025.
  • Over 5 years, Net Margin stood at 1.54% in 2021, then soared by 892bps to 15.23% in 2022, then crashed by -95bps to 0.69% in 2023, then soared by 1176bps to 8.83% in 2024, then crashed by -122bps to 1.94% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 1.94%, 23.49%, and 13.58% for Q4 2025, Q3 2025, and Q2 2025 respectively.